title: New targets and approaches in osteosarcoma.
abstract: Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.
authors.affiliation: Department of Pediatrics, Montefiore Medical Center and The Children's Hospital at Montefiore, Bronx, NY, United States.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Gill
authors.forename: Manpreet K
authors.initials: MK
authors.lastname: Ahluwalia
authors.forename: David
authors.initials: D
authors.lastname: Geller
authors.forename: Richard
authors.initials: R
authors.lastname: Gorlick
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents